CEO of SENS Foundation (Strategies for Engineered Negligible Senescence), Mike Kope, announced that Jason Hope pledged to contribute $500,000 to further the Foundation’s research in rejuvenation biotechnologies. The central focus of the Foundation is to apply this research to fight age-related disease.
Jason Hope is a highly recognized entrepreneur who is based in Scottsdale, Arizona. His philanthropic ventures encompass medical research and seeking disease cures, education, and computer technology with a special focus on the “internet of things.” Read more about Jason Hope at Wings Journal.
SENS Foundation was formed in 2009 for the express purpose of enabling rejuvenation research. The intent behind the research is to allow for repairing, or avoiding, the damage caused by the body’s normal metabolism as we age, so that no debilitating or even deadly pathologies arise.
It was through the Foundation’s Dr. Aubrey de Grey that Jason Hope found his interest in SENS Foundation piqued, inspiring him to make a generous donation. Diabetes, Alzheimer’s, lung disease and atherosclerosis, are just four of the diseases that affect aging Americans in large numbers.
With the half-million-dollar donation combined with other significant donations, SENS Foundation was able to create the Cambridge SENS Laboratory. With many worthy causes to choose from, Jason Hope advises others to consider several factors when making a decision to donate; these all figured in his contribution to SENS. His initial factor calls for one to discover their passions. In his case, the desire to aid in medical research was a driving reason for the donation to SENS Foundation. The other elements on his “list” are: whether an organization is local or national; the ability to donate time, money or both; and the importance of researching benefactor of a donation.
The legacy of Jason Hope’s contribution to SENS Foundation can already be seen in the furthering of its AGE-breaker development program. AGE is actually an acronym that stands for “advanced glycation end” products. These add to the degenerative process that can lead to development of the previously mentioned disease in addition to arthritis, osteoporosis, and Parkinson’s. While previous research did not yield significant results, it was discovered that humans have a different type of AGE than other animals (tissue of which was studied in research). Now, with these additional funds from contributors, research can continue with the specific study of human reaction to therapies that can negate the AGE’s in causing degenerative disease in aging adults.